Begin main content

Reports

We found 4896 result(s)

Emerging Drug List — Parecoxib Sodium

Published on: August 20, 2001
Result type: Reports
Product Line: Emerging Drug List

Tags

Analgesics, Injections, Pain, Anti-Inflammatory Agents, Ketorolac, Drug Therapy, Drug Approval, Drugs, COX-2 Inhibitors, Intravenous Injections, Postoperative Pain, Anti-Inflammatories, NSAIDs, Investigational Drugs, Anti-Inflammatory Agents, Non-Steroidal, Injections, Intravenous, Pain, Postoperative, Cyclooxygenase Inhibitors, Anesthesia, Intravenous, Postoperative, Non-Steroidal, Investigational, Parecoxib sodium, Valdecoxib, Pain killers, Parenteral administration, Anaesthesia, Post-surgical pain, Peri-operative pain, Regulatory status, Inhibiteur cyclooxygénase, Analgésiques, Anesthésie voie intraveineuse, Douleur, Douleur postopératoire, Antiinflammatoires nonstéroïdiens, Chimiothérapie, Autorisation mise sur marché médicament, Médicament phase recherche, parécoxib sodique, valdécoxib, inhibiteurs COX-2, analgésiques, injection intraveineuse, administration parentérale, anesthésie, douleur postopératoire, douleur post-chirurgicale, douleur péri-opératoire, anti-inflammatoires, AINS, réglementation, médicament expérimental

Novel antipsychotics for patients with bipolar disorder: A systematic review

Published on: August 15, 2001
Result type: Reports
Product Line: Health Technology Assessment, Technology Reports

Cite as: Shukla VK, McAuley L. Novel antipsychotics in patients with bipolar disorder: a systematic review. Ottawa: Canadian Coordinating Office for Health Technology Assessment (CCOHTA); 2001. Technology report no 16. Objectives The purpose of this assessment is to assess the efficacy of the novel antipsychotic drugs (olanzapine, risperidone, q...

Tags

Bipolar Disorder, Antipsychotic Agents, Risperidone, Clozapine, Depression, Bipolar disorder, Depression, trouble bipolaire, Manic, Olanzapine, Quetiapine, Chimiothérapie, Neuroleptiques, Dépression bipolaire, bipolaire, Antipsychotiques atypiques, Antipsychotiques

Drug Treatments for Alzheimer’s Disease: Efficacy, Outcome Measurements and Cost-Effectiveness

Published on: August 3, 2001
Result type: Reports
Product Line: Health Technology Assessment, Technology Overviews

Cite as: Husereau D, Wolfson C, Shukla VK. Drug treatments for Alzheimer's disease: efficacy, outcome measurements and cost-effectiveness. Ottawa: Canadian Coordinating Office for Health Technology Assessment (CCOHTA); 2001. Technology overview no 4. The Issue Alzheimer's disease (AD) is a devastating disorder of the elderly, and is expected to ...

Tags

Metrifonate, Ginkgo biloba, Alzheimer Disease, Drug Therapy, Cholinesterase Inhibitors, Economics, Pharmacoeconomics, Alzheimer, Maladie, Anticholinesterasiques, MA, Arbre aux quarante écus, Donépézil, Rivastigmine, Pharmaceutical, Alzheimers, Alzheimer’s, Donepezil, Cost and Cost Analysis

Non-penetrating glaucoma surgery using AquaFlow™ collagen implants

Published on: August 1, 2001
Result type: Reports

Summary AquaFlow™ is an absorbable collagen implant for use in non-penetrating surgery for primary open angle glaucoma. Its purpose is to facilitate drainage of fluid from the eye, thereby reducing intraocular pressure. AquaFlow™ is approved for use in Canada in medically refractory cases of primary open angle glaucoma. Non-penetrating glaucoma ...

Tags

Glaucoma, Aqueous Humor, Prostheses and Implants, Absorbable Implants, Intraocular Pressure, Equipment and Supplies, Device Approval, Aqueous Flare, Intraocular Fluid, Biodegradable Implants, Eye, Glaucoma, Open-Angle, Surgery, Medical Devices, Chirurgie, Diabetes, Eye/vision, Open-Angle, AquaFlow, Implants, Eye surgery, Non-penetrating surgery, Medical equipment, Regulatory status, Glaucome angle ouvert, Humeur aqueuse, Prothèse et implants, Implant résorbable, Pression intra-oculaire, Équipement et appareillage, Autorisation mise sur marché matériel, glaucome, humeur aqueuse, liquide intra-oculaire, implant, implant biodégradable, chirurgie oculaire, chirurgie non invasive, équipement médical, appareil médical, réglementation, collagen implant

Emerging Device List — Warm-Up® Therapy

Published on: August 1, 2001
Result type: Reports
Product Line: Emerging Technology List

Tags

Wound Healing, Bandages, Decubitus Ulcer, Varicose Ulcer, Diabetic Foot, Costs and Cost Analysis, Device Approval, Equipment and Supplies, Bed Sores, Wounds and Injuries, Medical Devices, Wounds and injuries, Warm-Up, Pressure ulcers, Leg ulcers, Diabetic ulcers, Foot ulcers, Regulatory status, Medical equipment, Cicatrisation, Pansement et Bandage, Escarre, Ulcère variqueux, Pied diabétique, Coût et analyse coût, Autorisation mise sur marché matériel, Équipement et appareillage, plaie de pression, escarre de décubitus, ulcère de jambe, ulcère diabétique, ulcère du pied, réglementation, équipement médical, appareil médical

Rosuvastatin: Do we need another statin?

Published on: August 1, 2001
Result type: Reports

Summary Rosuvastatin (CrestorTM) is a new synthetic agent for the treatment and prevention of lipid disorders, a risk factor for coronary heart disease. Rosuvastatin is undergoing phase III clinical trials. A New Drug Application was submitted to the U.S. Food and Drug Administration in June, 2001. No information on the regulatory status in Cana...

Tags

Hyperlipidemia, Hypercholesterolemia, Lipoproteins, LDL Cholesterol, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Anticholesteremic Agents, Drugs, Dyslipidemia, HMG-CoA Reductase Inhibitors, Fluorobenzenes, Cholesterol, Rosuvastatin, Investigational, Hyperlipidémies, Hypercholestérolémie, Cholestérol LDL, Inhibiteurs, hydroxyméthylglutaryl-CoA réductase, Hypocholestérolémiants, Rythme administration médicament, Chimiothérapie, low-density lipoprotein cholesterol, Statins, Inhibiteurs Hydroxymethylglutaryl-CoA Reductase, Cholestérol HDL, Hypolipemiants, Vaisseaux Coronaires, Maladies, Inhibiteurs de l’HMG-CoA réductase, LDL, HDL, Réduction AND lipides, Cardiopathie, Rosuvastatine, Crestor, ZD4522, Statines

Tacrolimus Ointment for the Treatment of Atopic Dermatitis

Published on: July 27, 2001
Result type: Reports

Tags

Dermatitis, Dermatologic Agents, Drug Therapy, Administration, Ointments, Costs and Cost Analysis, Canada, Tacrolimus, FK506, Eczema, Dermatology, Administration, Topical, Dermatitis, Atopic, Dermatology, Atopic, Topical, Protopic, Tsukubaenolide, Skin creams, Dermatitie atopique, Produits dermatologiques, Chimiothérapie, Voie externe, Pommade, Coût et analyse coût, Autorisation mise sur marché médicament, Médicament phase recherche, tsukubénolide, dermatite, crème pour la peau

Emerging Device List — TruScan™

Published on: July 23, 2001
Result type: Reports
Product Line: Emerging Technology List

Tags

Cervix Neoplasms, Electrodiagnosis, Mass Screening, Vaginal Smears, Device Approval, Equipment and Supplies, Cancer of the Cervix, Cancer, Medical Devices, Cancer, TruScan, Cervical cancer, Regulatory status, Medical equipment, Tumeur col utérus, Électrodiagnostic, Dépistage systématique, Frottis vaginal, Autorisation mise sur marché matériel, Équipement et appareillage, cancer cervical, cancer du col de l’utérus, réglementation, équipement médical, appareil médical

A Population-based Cohort Study of Surveillance Mammography After Treatment of Primary Breast Cancer

Published on: July 15, 2001
Result type: Reports
Product Line: Health Technology Assessment, Technology Reports

Cite as: Paszat L, Grunfeld E, van Walraven C, Coyle D, Sawka C, Yun J, McGahan L, Noorani H. A Population-based cohort Study of Surveillance Mammography After Treatment of Primary Breast Cancer. Ottawa: Canadian Coordinating Office for Health Technology Assessment (CCOHTA); 2001. Technology report no 15. Annual surveillance mammography after th...

Tags

Cancer, Breast Neoplasms, Breast, Mammography, Mass Screening, Breast Cancer, Cancer, cancer du sein, Breast cancer, Tumeur sein, Mammographie, Mammograms, Cliché mammaire, bénéfice, Dépistage systématique, Breast cancer screening, Dépistage du cancer du sein

Oxygen carriers ”blood substitutes”

Published on: July 1, 2001
Result type: Reports

Summary A number of oxygen carriers, or "blood substitutes", are undergoing clinical trials. One product (Hemopure® ) was recently licensed for use in South Africa. Another, (Hemolink™) may soon be approved for marketing in Canada. Most trials of oxygen carriers have focused on their use in surgery, primarily as a way to minimize the need for al...

Tags

Blood Substitutes, Oxygen, Hemoglobins, Fluorocarbons, Hemodilution, Costs and Cost Analysis, Drug Approval, Drugs, Artificial Blood, Artificial Erythrocytes, Artificial Hemoglobin, Erythrocyte Substitutes, Hemoglobin Substitutes, Red Cell Substitutes, Fluorocarbon Emulsions, Perfluorocarbons, Investigational Drugs, Blood, Surgery, Surgical Procedures, Operative, Investigational, O2, Oxygen carriers, HBOCs, Hemopure, Hemolink, PolyHeme, Oxygent, HemAssist, Gelenpol, Perftoran, VTX-PHP, Regulatory status, Succédanés sanguins, Oxygène, Hémoglobines, Fluorocarbones, Intervention chirurgicale, Coût et analyse coût, Autorisation mise sur marché médicament, Médicament phase recherche, sang artificiel, érythrocyte artificiel, hémoglobine artificielle, substitut d’érythrocytes, substitut d’hémoglobine, substitut de globules rouges, transporteur d’oxygène, transporteur d’oxygène à base d’hémoglobine, émulsion de perfluorocarbure, perfluorocarbure, réglementation, médicament expérimental